AOC-1020

Avidity Biosciences, Inc. · Phase 3 active Small molecule Quality 0/100

At a glance

Generic name	AOC-1020
Also known as	del-brax
Sponsor	Avidity Biosciences, Inc.
Modality	Small molecule
Phase	Phase 3

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

A Study to Evaluate Del-brax (Also Referred to as AOC 1020) in Participants With FSHD (PHASE3)
Phase 1/2 Study of AOC 1020 in Participants With Facioscapulohumeral Muscular Dystrophy (FSHD) (PHASE1, PHASE2)
Phase 2 Open-label Extension Study of AOC 1020 in Participants with Facioscapulohumeral Muscular Dystrophy (FSHD) (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

AOC-1020 CI brief — competitive landscape report
AOC-1020 updates RSS · CI watch RSS
Avidity Biosciences, Inc. portfolio CI